Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
6 "Jung Ho Im"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Gastrointestinal cancer
Combined High-Dose Radiotherapy with Sequential Gemcitabine-Cisplatin Based Chemotherapy Increase the Resectability and Survival in Locally Advanced Unresectable Intrahepatic Cholangiocarcinoma: A Multi-institutional Cohort Study
Jung Ho Im, Jeong Il Yu, Tae Hyun Kim, Tae Gyu Kim, Jun Won Kim, Jinsil Seong
Cancer Res Treat. 2024;56(3):838-846.   Published online January 2, 2024
DOI: https://doi.org/10.4143/crt.2023.886
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The locally advanced unresectable intrahepatic cholangiocarcinoma (ICC) has detrimental oncological outcomes. In this study, we aimed to investigate the efficacy of radiotherapy in patients with locally advanced unresectable ICC.
Materials and Methods
Between 2001 and 2021, 116 patients were identified through medical record who underwent radiotherapy for locally advanced unresectable ICC. The resectability of ICC is determined by the multidisciplinary team at each institution. Overall survival (OS) were analyzed using the Kaplan-Meier method, and prognostic factors were analyzed using the Cox proportional hazards model.
Results
The median equivalent radiotherapy dose in 2 Gy fractions (EQD2) was 52 Gy (range, 30 to 110 Gy). Forty-seven patients (40.5%) received sequential gemcitabine-cisplatin based chemotherapy (GEM-CIS CTx). Multivariate analysis identified two risk factors, EQD2 of ≥ 60 Gy and application of sequential GEM-CIS CTx for OS. Patients were grouped by these two risk factors: group 1, EQD2 ≥ 60 Gy with sequential GEM-CIS CTx (n=25); group 2, EQD2 < 60 Gy with sequential GEM-CIS CTx or fluoropyrimidine-based concurrent chemoradiotherapy (n=70); and group 3, radiotherapy alone (n=21). Curative resection was more frequently undergone in group 1 than in groups 2 or 3 (28% vs. 8.6% vs. 0%, respectively). Consequently, OS was significantly better in group 1 than in groups 2 and 3 (p < 0.05).
Conclusion
Combined high-dose radiotherapy with sequential GEM-CIS CTx improved oncologic outcomes in patients with locally advanced unresectable ICC. Further prospective studies are required to validate these findings.
  • 3,000 View
  • 133 Download
Close layer
Risk Factors for Distant Metastasis in Extrahepatic Bile Duct Cancer after Curative Resection (KROG 1814)
Younghee Park, Tae Hyun Kim, Kyubo Kim, Jeong Il Yu, Wonguen Jung, Jinsil Seong, Woo Chul Kim, Jin Hwa Choi, Ah Ram Chang, Bae Kwon Jeong, Byoung Hyuck Kim, Tae Gyu Kim, Jin Hee Kim, Hae Jin Park, Hyun Soo Shin, Jung Ho Im, Eui Kyu Chie
Cancer Res Treat. 2024;56(1):272-279.   Published online July 31, 2023
DOI: https://doi.org/10.4143/crt.2023.616
AbstractAbstract PDFPubReaderePub
Purpose
Risk factors predicting distant metastasis (DM) in extrahepatic bile duct cancer (EHBDC) patients treated with curative resection were investigated.
Materials and Methods
Medical records of 1,418 EHBDC patients undergoing curative resection between Jan 2000 and Dec 2015 from 14 institutions were reviewed. After resection, 924 patients (67.6%) were surveilled without adjuvant therapy, 297 (21.7%) were treated with concurrent chemoradiotherapy (CCRT) and 148 (10.8%) with CCRT followed by chemotherapy. To exclude the treatment effect from innate confounders, patients not treated with adjuvant therapy were evaluated.
Results
After a median follow-up of 36.7 months (range, 2.7 to 213.2 months), the 5-year distant metastasis-free survival (DMFS) rate was 57.7%. On multivariate analysis, perihilar or diffuse tumor (hazard ratio [HR], 1.391; p=0.004), poorly differentiated histology (HR, 2.014; p < 0.001), presence of perineural invasion (HR, 1.768; p < 0.001), positive nodal metastasis (HR, 2.670; p < 0.001) and preoperative carbohydrate antigen (CA) 19-9 ≥ 37 U/mL (HR, 1.353; p < 0.001) were significantly associated with inferior DMFS. The DMFS rates significantly differed according to the number of these risk factors. For validation, patients who underwent adjuvant therapy were evaluated. In patients with ≥ 3 factors, additional chemotherapy after CCRT resulted in a superior DMFS compared with CCRT alone (5-year rate, 47.6% vs. 27.7%; p=0.001), but the benefit of additional chemotherapy was not observed in patients with 0-2 risk factors.
Conclusion
Tumor location, histologic differentiation, perineural invasion, lymph node metastasis, and preoperative CA 19-9 level predicted DM risk in resected EHBDC. These risk factors might help identifying a subset of patients who could benefit from additional chemotherapy after resection.
  • 3,237 View
  • 190 Download
Close layer
CNS cancer
Suggestions for Escaping the Dark Ages for Pediatric Diffuse Intrinsic Pontine Glioma Treated with Radiotherapy: Analysis of Prognostic Factors from the National Multicenter Study
Hyun Ju Kim, Joo Ho Lee, Youngkyong Kim, Do Hoon Lim, Shin-Hyung Park, Seung Do Ahn, In Ah Kim, Jung Ho Im, Jae Wook Chung, Joo-Young Kim, Il Han Kim, Hong In Yoon, Chang-Ok Suh
Cancer Res Treat. 2023;55(1):41-49.   Published online March 4, 2022
DOI: https://doi.org/10.4143/crt.2021.1514
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This multicenter retrospective study aimed to investigate clinical, radiologic, and treatment-related factors affecting survival in patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) treated with radiotherapy.
Materials and Methods
Patients aged <30 years who underwent radiotherapy as an initial treatment for DIPG between 2000 and 2018 were included; patients who did not undergo magnetic resonance imaging at diagnosis and those with pathologically diagnosed grade I glioma were excluded. We examined medical records of 162 patients collected from 10 participating centers in Korea. The patients’ clinical, radiological, molecular, and histopathologic characteristics, and treatment responses were evaluated to identify the prognosticators for DIPG and estimate survival outcomes.
Results
The median follow-up period was 10.8 months (interquartile range, 7.5 to 18.1). The 1- and 2-year overall survival (OS) rates were 53.5% and 19.0%, respectively, with a median OS of 13.1 months. Long-term survival rate (≥ 2 years) was 16.7%, and median OS was 43.6 months. Age (< 10 years), poor performance status, treatment before 2010, and post-radiotherapy necrosis were independently associated with poor OS in multivariate analysis. In patients with increased post-radiotherapy necrosis, the median OS estimates were 13.3 months and 11.4 months with and without bevacizumab, respectively (p=0.138).
Conclusion
Therapeutic strategy for DIPG has remained unchanged over time, and the associated prognosis remains poor. Our findings suggest that appropriate efforts are needed to reduce the occurrence of post-radiotherapy necrosis. Further well-designed clinical trials are recommended to improve the poor prognosis observed in DIPG patients.

Citations

Citations to this article as recorded by  
  • Advancements in Image-Based Models for High-Grade Gliomas Might Be Accelerated
    Guido Frosina
    Cancers.2024; 16(8): 1566.     CrossRef
  • The relationship between imaging features, therapeutic response, and overall survival in pediatric diffuse intrinsic pontine glioma
    Xiaojun Yu, Mingyao Lai, Juan Li, Lichao Wang, Kunlin Ye, Dong Zhang, Qingjun Hu, Shaoqun Li, Xinpeng Hu, Qiong Wang, Mengjie Ma, Zeyu Xiao, Jiangfen Zhou, Changzheng Shi, Liangping Luo, Linbo Cai
    Neurosurgical Review.2024;[Epub]     CrossRef
  • Current status and advances to improving drug delivery in diffuse intrinsic pontine glioma
    Lauren M. Arms, Ryan J. Duchatel, Evangeline R. Jackson, Pedro Garcia Sobrinho, Matthew D. Dun, Susan Hua
    Journal of Controlled Release.2024; 370: 835.     CrossRef
  • Pediatric diffuse intrinsic pontine glioma radiotherapy response prediction: MRI morphology and T2 intensity-based quantitative analyses
    Xiaojun Yu, Shaoqun Li, Wenfeng Mai, Xiaoyu Hua, Mengnan Sun, Mingyao Lai, Dong Zhang, Zeyu Xiao, Lichao Wang, Changzheng Shi, Liangping Luo, Linbo Cai
    European Radiology.2024; 34(12): 7962.     CrossRef
  • 5,614 View
  • 222 Download
  • 7 Web of Science
  • 4 Crossref
Close layer
The Role of Postoperative Radiotherapy in Intracranial Solitary Fibrous Tumor/Hemangiopericytoma: A Multi-institutional Retrospective Study (KROG 18-11)
Joo Ho Lee, Seung Hyuck Jeon, Chul-Kee Park, Sung-Hye Park, Hong In Yoon, Jong Hee Chang, Chang-Ok Suh, Su Jeong Kang, Do Hoon Lim, In Ah Kim, Jin Hee Kim, Jung Ho Im, Sung-Hwan Kim, Chan Woo Wee, Il Han Kim
Cancer Res Treat. 2022;54(1):65-74.   Published online March 24, 2021
DOI: https://doi.org/10.4143/crt.2021.142
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to evaluate the role of postoperative radiotherapy (PORT) in intracranial solitary fibrous tumor/hemangiopericytoma (SFT/HPC).
Materials and Methods
A total of 133 patients with histologically confirmed HPC were included from eight institutions. Gross total resection (GTR) and subtotal resection (STR) were performed in 86 and 47 patients, respectively. PORT was performed in 85 patients (64%). The prognostic effects of sex, age, performance, World Health Organization (WHO) grade, location, size, Ki-67, surgical extent, and PORT on local control (LC), distant metastasis-free survival (DMFS), progression-free survival (PFS), and overall survival (OS) were estimated by univariate and multivariate analyses.
Results
The 10-year PFS, and OS rates were 45%, and 71%, respectively. The multivariate analysis suggested that PORT significantly improved LC (p < 0.001) and PFS (p < 0.001). The PFS benefit of PORT was maintained in the subgroup of GTR (p=0.001), WHO grade II (p=0.001), or STR (p < 0.001). In the favorable subgroup of GTR and WHO grade II, PORT was also significantly related to better PFS (p=0.028). WHO grade III was significantly associated with poor DMFS (p=0.029). In the PORT subgroup, the 0-0.5 cm margin of the target volume showed an inferior LC to a large margin with 1.0-2.0 cm (p=0.021). Time-dependent Cox proportion analysis showed that distant failures were significantly associated with poor OS (p=0.003).
Conclusion
This multicenter study supports the role of PORT in disease control of intracranial SFT/HPC, irrespective of the surgical extent and grade. For LC, PORT should enclose the tumor bed with sufficient margin.

Citations

Citations to this article as recorded by  
  • Does Adjuvant Radiotherapy Enhance Survival in Intracranial Solitary Fibrous Tumor Patients?
    Sakhr Alshwayyat, Haya Kamal, Tala Abdulsalam Alshwayyat, Mustafa Alshwayyat, Mesk Alkhatib, Ayah Erjan
    World Neurosurgery.2025; 194: 123545.     CrossRef
  • Application and effect evaluation of microsurgical resection combined with intensity-modulated radiation therapy in the treatment of intracranial solitary fibrous tumor/hemangiopericytoma
    Jingcheng Jiang, Xiaoqin Qu, Han Wang, Chao Zhang, Qingshan Deng, Xiaoping Xu, Jun Qiu, Lihua Qu, Yong Yi
    Medicine.2025; 104(6): e41336.     CrossRef
  • Development of an MRI‐Based Comprehensive Model Fusing Clinical, Radiomics and Deep Learning Models for Preoperative Histological Stratification in Intracranial Solitary Fibrous Tumor
    Xiaohong Liang, Kaiqiang Tang, Xiaoai Ke, Jian Jiang, Shenglin Li, Caiqiang Xue, Juan Deng, Xianwang Liu, Cheng Yan, Mingzi Gao, Junlin Zhou, Liqin Zhao
    Journal of Magnetic Resonance Imaging.2024; 60(2): 523.     CrossRef
  • Meningeal Solitary Fibrous Tumor: A Single-Center Retrospective Cohort Study
    Siyer Roohani, Yasemin Alberti, Maximilian Mirwald, Felix Ehret, Carmen Stromberger, Soleiman Fabris Roohani, Katja Bender, Anne Flörcken, Sven Märdian, Daniel Zips, David Kaul, Manish Charan
    Sarcoma.2024; 2024: 1.     CrossRef
  • Repeated Radiation Therapy of Recurrent Solitary Fibrous Tumors of the Brain: A Medical Case History Over 20 Years
    Anna Carla Piccardo, Sabrina Gurdschinski, Sybille Spieker, Christof Renner, Piotr Czapiewski, Markus Wösle, I. Frank Ciernik
    Advances in Radiation Oncology.2024; 9(4): 101426.     CrossRef
  • Intracranial solitary fibrous tumors: Clinical, radiological, and histopathological insights along with review of literature
    Adil Aziz Khan, Sana Ahuja, Dipanker Singh Mankotia, Sufian Zaheer
    Pathology - Research and Practice.2024; 260: 155456.     CrossRef
  • Central nervous system solitary fibrous tumors: Case series in accordance with the WHO 2021 reclassification. Framework for patient surveillance
    V. Matthijs, R. Beckers, C. Vanden Broecke, F. Dedeurwaerdere, J. Van Dorpe, D. Vanhauwaert, G. Hallaert
    Acta Neurochirurgica.2024;[Epub]     CrossRef
  • Recurrence of Solitary Fibrous Tumor in the Spinal Cord Following Gross Total and Subtotal Resection: A Case Report of Recurrence 19 Years of Post-total Resection and Systematic Literature Review
    Satoka SHIDOH, Kazutoshi HIDA, Yoshitaka ODA, Toru SASAMORI, Prabin SHRESTHA, Jangbo LEE, Satoshi YAMAGUCHI
    NMC Case Report Journal.2024; 11: 297.     CrossRef
  • The role of radiotherapy in intracranial hemangiopericytoma/solitary fibrous tumors
    Nuri Kaydıhan, Gözde Yazıcı, Petek Erpolat, Serra Kamer, Burak Erdemci, Emine Canyılmaz, Beste Melek Atasoy, Dicle Aslan, Ela Delikgöz Soykut, Enis Özyar, Fatih Demircioğlu, Fazilet Öner Dinçbaş, Meltem Kirli Bolukbas, Ramazan Aksu, Selvi Tabak Dinçer, Ya
    Strahlentherapie und Onkologie.2024;[Epub]     CrossRef
  • The Role of Radical Radiotherapy in Sinonasal Myopericytoma: A Case Report and Literature Overview
    Anna Merlotti, Stefania Martini, Riccardo Vigna Taglianti, Alessia Reali, Giuseppe Signorini, Silvana Parisi, Francesca De Felice
    EMJ Oncology.2023;[Epub]     CrossRef
  • Intracranial Solitary Fibrous Tumour Management: A French Multicentre Retrospective Study
    Marine Lottin, Alexandre Escande, Luc Bauchet, Marie Albert-Thananayagam, Maël Barthoulot, Matthieu Peyre, Mathieu Boone, Sonia Zouaoui, Jacques Guyotat, Guillaume Penchet, Johan Pallud, Henry Dufour, Evelyne Emery, Michel Lefranc, Sébastien Freppel, Houm
    Cancers.2023; 15(3): 704.     CrossRef
  • Solitary fibrous tumor of the central nervous system invading and penetrating the skull: A case report
    Qiyan Lin, Jiabin Zhu, Xiaofeng Zhang
    Oncology Letters.2023;[Epub]     CrossRef
  • Impact of extent of resection and postoperative radiotherapy on survival outcomes in intracranial solitary fibrous tumors: a systematic review and meta-analysis
    Sae Min Kwon, Min Kyun Na, Kyu-Sun Choi, Tae Ho Lim, Hyungoo Shin, Juncheol Lee, Heekyung Lee, Wonhee Kim, Youngsuk Cho, Jae Guk Kim, Chiwon Ahn, Bo-Hyoung Jang
    Neurosurgical Review.2023;[Epub]     CrossRef
  • Radiotherapy for rare primary brain tumors
    E. Mesny, P. Lesueur
    Cancer/Radiothérapie.2023; 27(6-7): 599.     CrossRef
  • Complete Resection of a Torcular Herophili Hemangiopericytoma without Sinus Reconstruction: A Case Report and Review of the Literature
    Salah-Edine Safi, Julie Godfrain, Herbert Rooijakkers, Frederic Collignon, Mario Ganau
    Case Reports in Surgery.2023; 2023: 1.     CrossRef
  • Surgical Management of Craniospinal Axis Solitary Fibrous Tumors: A Single-Institution Case Series and Comprehensive Review of the Literature
    Anthony J. Piscopo, A. J. Chowdhury, Nahom Teferi, Sarah Lee, Meron Challa, Michael Petronek, Kathryn Eschbacher, Girish Bathla, John M. Buatti, Patrick Hitchon
    Neurosurgery.2023;[Epub]     CrossRef
  • Clinical Features, Management, and Prognostic Factors of Intracranial Solitary Fibrous Tumor
    Jingdian Liu, Sisi Wu, Kai Zhao, Junwen Wang, Kai Shu, Ting Lei
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Toward Better Understanding and Management of Solitary Fibrous Tumor
    Karineh Kazazian, Elizabeth G. Demicco, Marc de Perrot, Dirk Strauss, Carol J. Swallow
    Surgical Oncology Clinics of North America.2022; 31(3): 459.     CrossRef
  • Effect of Different Treatments for Intracranial Solitary Fibrous Tumors: Retrospective Analysis of 31 Patients
    Qinghua Li, Wenshuai Deng, Peng Sun
    World Neurosurgery.2022; 166: e60.     CrossRef
  • Sixteen-Year Follow-Up in a Cavernous Sinus Hemangiopericytoma: Improved Outcomes over Radiotherapy Advances
    Beatrice Detti, Lilia Bardoscia, Antonio Rosario Pisani, Salvatore Cozzi, Manuele Roghi, Paolo Mammucci, Angela Sardaro
    Brain Sciences.2022; 12(9): 1209.     CrossRef
  • Solitary Fibrous Tumor of the Jugular Foramen: A Case Report and Review of the Histopathologic Classification
    Mallory Raymond, Philip Ryan Elvis, Tiffany Baker, William Alexander Vandergrift, Theodore McRackan
    Otology & Neurotology.2022; 43(10): e1208.     CrossRef
  • A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons
    Javier Martin-Broto, Jose L. Mondaza-Hernandez, David S. Moura, Nadia Hindi
    Cancers.2021; 13(12): 2913.     CrossRef
  • Intradural Extramedullary Solitary Fibrous Tumor of the Thoracic Spinal Cord
    Zachary T Olmsted, Joanna Tabor, Omer Doron, Hossein Hosseini, Daniel Schneider, Ross Green, Samuel J Wahl, Daniel M Scuibba, Randy S D'Amico
    Cureus.2021;[Epub]     CrossRef
  • 8,939 View
  • 350 Download
  • 21 Web of Science
  • 23 Crossref
Close layer
Surgery Alone Versus Surgery Followed by Chemotherapy and Radiotherapy in Resected Extrahepatic Bile Duct Cancer: Treatment Outcome Analysis of 336 Patients
Jung Ho Im, Jinsil Seong, Ik Jae Lee, Joon Seong Park, Dong Sup Yoon, Kyung Sik Kim, Woo Jung Lee, Kyung Ran Park
Cancer Res Treat. 2016;48(2):583-595.   Published online July 22, 2015
DOI: https://doi.org/10.4143/crt.2015.091
AbstractAbstract PDFPubReaderePub
Purpose
This study analyzed the outcomes of patients with resected extrahepatic bile duct cancer (EHBDC) in order to clarify the role of adjuvant treatments in these patients.
Materials and Methods
A total of 336 patients with EHBDC who underwent curative resection between 2001 and 2010 were analyzed retrospectively. The treatment types were as follows: surgery alone (n=168), surgery with chemotherapy (CTx, n=90), surgery with radiotherapy (RT) alone (n=29), and surgery with chemoradiotherapy (CRT, n=49).
Results
The median follow-up period was 63 months. The 5-year rates of locoregional failure-free survival (LRFFS), distant metastasis-free survival (DMFS), progression-free survival (PFS), and overall survival (OS) for all patients were 56.5%, 59.7%, 36.6%, and 42.0%, respectively. In multivariate analysis, surgery with RT and CRT was a significant prognostic factor for LRFFS, and surgery with CTx was a significant prognostic factor for DMFS, and surgery with CTx, RT, and CRT was a significant prognostic factor for PFS (p < 0.05). Surgery with CTx and CRT showed association with superior OS (p < 0.05), and surgery with RT had marginal significance (p=0.078). In multivariate analysis of the R1 resection patients, surgery with CRT showed significant association with OS (p < 0.05).
Conclusion
Adjuvant RT and CTx may be helpful in improving clinical outcomes of patients with resected EHBDC who have a high risk of disease recurrence, particularly R1 resection patients. Conduct of additional prospective, larger-scale studies will be required in order to confirm the benefit of adjuvant RT and CTx in these patients.

Citations

Citations to this article as recorded by  
  • Risk Factors for Distant Metastasis in Extrahepatic Bile Duct Cancer after Curative Resection (KROG 1814)
    Younghee Park, Tae Hyun Kim, Kyubo Kim, Jeong Il Yu, Wonguen Jung, Jinsil Seong, Woo Chul Kim, Jin Hwa Choi, Ah Ram Chang, Bae Kwon Jeong, Byoung Hyuck Kim, Tae Gyu Kim, Jin Hee Kim, Hae Jin Park, Hyun Soo Shin, Jung Ho Im, Eui Kyu Chie
    Cancer Research and Treatment.2024; 56(1): 272.     CrossRef
  • NIR-Responsive Methotrexate-Modified Iron Selenide Nanorods for Synergistic Magnetic Hyperthermic, Photothermal, and Chemodynamic Therapy
    Senthilkumar Thirumurugan, Kayalvizhi Samuvel Muthiah, Yu-Chien Lin, Udesh Dhawan, Wai-Ching Liu, An-Ni Wang, Xinke Liu, Michael Hsiao, Ching-Li Tseng, Ren-Jei Chung
    ACS Applied Materials & Interfaces.2024; 16(20): 25622.     CrossRef
  • Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer
    L.-T. Chen, A. Vogel, C. Hsu, M.-H. Chen, W. Fang, E.A. Pangarsa, A. Sharma, M. Ikeda, J.O. Park, C.K. Tan, E. Regala, D. Tai, S. Tanasanvimon, C. Charoentum, C.E. Chee, A. Lui, J. Sow, D.-Y. Oh, M. Ueno, A. Ramaswamy, W.S. Jeo, J. Zhou, G. Curigliano, T.
    ESMO Open.2024; 9(8): 103647.     CrossRef
  • A Mn-doped calcium phosphate nanoparticle-based multifunctional nanocarrier for targeted drug delivery and cellular MR imaging
    Chaohui Zhou, Shenglei Hou, Chusen Huang, Nengqin Jia
    Journal of Nanoparticle Research.2022;[Epub]     CrossRef
  • Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma
    Xing Chen, Jinpeng Du, Jiwei Huang, Yong Zeng, Kefei Yuan
    Journal of Clinical and Translational Hepatology.2022; 10(3): 553.     CrossRef
  • Machine Learning: A New Prospect in Multi-Omics Data Analysis of Cancer
    Babak Arjmand, Shayesteh Kokabi Hamidpour, Akram Tayanloo-Beik, Parisa Goodarzi, Hamid Reza Aghayan, Hossein Adibi, Bagher Larijani
    Frontiers in Genetics.2022;[Epub]     CrossRef
  • Clinical efficacy of adjuvant treatments for patients with resected biliary tract cancer: a systematic review and network meta-analysis
    Ye Chen, Baoxia Zhang, Chang Liu, Ye Cao, Cheng Lyu, Meng Qiu
    BMJ Open.2022; 12(4): e051421.     CrossRef
  • A two-fold interpenetration pillar-layered metal-organic frameworks based on BODIPY for chemo-photodynamic therapy
    Yang Meng, Yingying Du, Yanxin Lin, Yu Su, Ruonan Li, Yaqing Feng, Shuxian Meng
    Dyes and Pigments.2021; 188: 109174.     CrossRef
  • Adjuvant Therapy for Resectable Biliary Tract Cancer: A Bayesian Network Analysis
    Xiuqiong Chen, Fanqiao Meng, Hua Xiong, Yanmei Zou
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • The Therapeutic Potential of the Anticancer Activity of Fucoidan: Current Advances and Hurdles
    Jun-O. Jin, Pallavi Singh Chauhan, Ananta Prasad Arukha, Vishal Chavda, Anuj Dubey, Dhananjay Yadav
    Marine Drugs.2021; 19(5): 265.     CrossRef
  • The Role of Adjuvant Chemoradiotherapy in Nonhilar Extrahepatic Bile Duct Cancer: A Long-Term Single-Institution Analysis
    Won Ick Chang, Byoung Hyuck Kim, Hyun-Cheol Kang, Kyubo Kim, Kyung-Hun Lee, Do-Youn Oh, Hongbeom Kim, Wooil Kwon, Jin-Young Jang, Eui Kyu Chie
    International Journal of Radiation Oncology*Biology*Physics.2021; 111(2): 395.     CrossRef
  • A pH-sensitive drug delivery system based on folic acid-targeted HBP-modified mesoporous silica nanoparticles for cancer therapy
    Yan Li, Shuai Wang, Fang Xiang Song, Li Zhang, Wei Yang, Hong Xia Wang, Qian Lin Chen
    Colloids and Surfaces A: Physicochemical and Engineering Aspects.2020; 590: 124470.     CrossRef
  • A meta-analysis of the efficacy of postoperative adjuvant radiotherapy versus no radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma
    Bixin Ren, Qi Guo, Yongqiang Yang, Lei Liu, Shaohua Wei, Wei Chen, Ye Tian
    Radiation Oncology.2020;[Epub]     CrossRef
  • Current standards and future perspectives in adjuvant treatment for biliary tract cancers
    Angela Lamarca, Julien Edeline, Mairéad G McNamara, Richard A Hubner, Masato Nagino, John Bridgewater, John Primrose, Juan W Valle
    Cancer Treatment Reviews.2020; 84: 101936.     CrossRef
  • Rectal stenosis due to solitary pelvic recurrence of hilar cholangiocarcinoma
    Ikuma Shioi, Yusuke Yamaoka, Akio Shiomi, Hiroyasu Kagawa, Hitoshi Hino, Shoichi Manabe, Daisuke Aizawa
    JGH Open.2020; 4(5): 1014.     CrossRef
  • Role of adjuvant (chemo)radiotherapy for resected extrahepatic cholangiocarcinoma: a meta-analysis
    Xin-qi Shi, Jing-yu Zhang, Hua Tian, Ling-na Tang, Ai-lin Li
    Journal of Zhejiang University-SCIENCE B.2020; 21(7): 549.     CrossRef
  • Italian Clinical Practice Guidelines on Cholangiocarcinoma – Part II: Treatment
    Domenico Alvaro, Cesare Hassan, Vincenzo Cardinale, Guido Carpino, Luca Fabris, Enrico Gringeri, Vincenza Granata, Massimiliano Mutignani, Helen Morement, Felice Giuliante, Alfredo Guglielmi, Lorenzo Ridola, Giuseppe Tonini, Marco Marzioni, Gianluca Grazi
    Digestive and Liver Disease.2020; 52(12): 1430.     CrossRef
  • The Evolving Role of Radiation Therapy in the Treatment of Biliary Tract Cancer
    Eleni Gkika, Maria A. Hawkins, Anca-Ligia Grosu, Thomas B. Brunner
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Sequentially self-assembled polysaccharide-based nanocomplexes for combined chemotherapy and photodynamic therapy of breast cancer
    Yaping Wang, Ming Yang, Junmin Qian, Weijun Xu, Jinlei Wang, Guanghui Hou, Lijie Ji, Aili Suo
    Carbohydrate Polymers.2019; 203: 203.     CrossRef
  • The effect of adjuvant chemotherapy in resectable cholangiocarcinoma: A meta-analysis and systematic review
    Ming-Liang Wang, Zhang-Yan Ke, Shuai Yin, Chen-Hai Liu, Qiang Huang
    Hepatobiliary & Pancreatic Diseases International.2019; 18(2): 110.     CrossRef
  • Electronic and Thermal Properties of Graphene and Recent Advances in Graphene Based Electronics Applications
    Mingyu Sang, Jongwoon Shin, Kiho Kim, Ki Jun Yu
    Nanomaterials.2019; 9(3): 374.     CrossRef
  • Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline
    Rachna T. Shroff, Erin B. Kennedy, Melinda Bachini, Tanios Bekaii-Saab, Christopher Crane, Julien Edeline, Anthony El-Khoueiry, Mary Feng, Matthew H.G. Katz, John Primrose, Heloisa P. Soares, Juan Valle, Shishir K. Maithel
    Journal of Clinical Oncology.2019; 37(12): 1015.     CrossRef
  • Risk factors associated with locoregional failure and estimation of survival after curative resection for patients with distal bile duct cancer
    Jung Ho Im, Joon Seong Park, Dong Sup Yoon, Dong Ki Lee, Jun Won Kim, Ik Jae Lee
    Scientific Reports.2019;[Epub]     CrossRef
  • Self-assembly of photosensitive and chemotherapeutic drugs for combined photodynamic-chemo cancer therapy with real-time tracing property
    Shengtao Wang, Jingtao Li, Zhou Ye, Jieling Li, Anhe Wang, Jing Hu, Shuo Bai, Jian Yin
    Colloids and Surfaces A: Physicochemical and Engineering Aspects.2019; 574: 44.     CrossRef
  • Radiation therapy for extrahepatic bile duct cancer: Current evidences and future perspectives
    Taeryool Koo, Hae Jin Park, Kyubo Kim
    World Journal of Clinical Cases.2019; 7(11): 1242.     CrossRef
  • Graphene Quantum Dots‐Capped Magnetic Mesoporous Silica Nanoparticles as a Multifunctional Platform for Controlled Drug Delivery, Magnetic Hyperthermia, and Photothermal Therapy
    Xianxian Yao, Xingxing Niu, Kexin Ma, Ping Huang, Julia Grothe, Stefan Kaskel, Yufang Zhu
    Small.2017;[Epub]     CrossRef
  • Resection margin influences survival after pancreatoduodenectomy for distal cholangiocarcinoma
    Terence C. Chua, Anubhav Mittal, Jenny Arena, Amy Sheen, Anthony J. Gill, Jaswinder S. Samra
    The American Journal of Surgery.2017; 213(6): 1072.     CrossRef
  • Mesoporous Silica Nanoparticles Capped with Graphene Quantum Dots for Potential Chemo–Photothermal Synergistic Cancer Therapy
    Xianxian Yao, Zhengfang Tian, Jiaxing Liu, Yufang Zhu, Nobutaka Hanagata
    Langmuir.2017; 33(2): 591.     CrossRef
  • Targeted Chemo-Photodynamic Combination Platform Based on the DOX Prodrug Nanoparticles for Enhanced Cancer Therapy
    Yumin Zhang, Fan Huang, Chunhua Ren, Lijun Yang, Jianfeng Liu, Zhen Cheng, Liping Chu, Jinjian Liu
    ACS Applied Materials & Interfaces.2017; 9(15): 13016.     CrossRef
  • Adjuvant concurrent chemoradiotherapy with low-dose daily cisplatin for extrahepatic bile duct cancer
    Sang-Won Kim, O Kyu Noh, Ji Hun Kim, Mison Chun, Young-Taek Oh, Seok Yun Kang, Hyun Woo Lee, Rae Woong Park, Dukyong Yoon
    Cancer Chemotherapy and Pharmacology.2017; 79(6): 1161.     CrossRef
  • Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis
    Michele Ghidini, Gianluca Tomasello, Andrea Botticelli, Sandro Barni, Giampietro Zabbialini, Silvia Seghezzi, Rodolfo Passalacqua, Chiara Braconi, Fausto Petrelli
    HPB.2017; 19(9): 741.     CrossRef
  • Characterisation of the immune-related transcriptome in resected biliary tract cancers
    Michele Ghidini, Luciano Cascione, Pietro Carotenuto, Andrea Lampis, Francesco Trevisani, Maria Chiara Previdi, Jens C. Hahne, Ian Said-Huntingford, Maya Raj, Alessandro Zerbi, Claudia Mescoli, Umberto Cillo, Massimo Rugge, Massimo Roncalli, Guido Torzill
    European Journal of Cancer.2017; 86: 158.     CrossRef
  • Over 700 Whipples for Pancreaticobiliary Malignancies: Postoperative Morbidity Is an Additional Negative Prognostic Factor for Distal Bile Duct Cancer
    Stefano Andrianello, Giovanni Marchegiani, Giuseppe Malleo, Borislav Chavdarov Rusev, Aldo Scarpa, Deborah Bonamini, Laura Maggino, Claudio Bassi, Roberto Salvia
    Journal of Gastrointestinal Surgery.2017; 21(3): 527.     CrossRef
  • A long survivor with local relapse of hilar cholangiocarcinoma after R1 surgery treated with chemoradiotherapy: a case report and literature review
    Hirohisa Okabe, Akira Chikamoto, Masataka Maruno, Daisuke Hashimoto, Katsunori Imai, Katsunobu Taki, Kota Arima, Takatoshi Ishiko, Hideaki Uchiyama, Toru Ikegami, Norifumi Harimoto, Shinji Itoh, Tomoharu Yoshizumi, Toru Beppu, Hideo Baba, Yoshihiko Maehar
    Surgical Case Reports.2016;[Epub]     CrossRef
  • miR-1246 and miR-4644 in salivary exosome as potential biomarkers for pancreatobiliary tract cancer
    Tatsuya Machida, Takaaki Tomofuji, Takayuki Maruyama, Toshiki Yoneda, Daisuke Ekuni, Tetsuji Azuma, Hisataka Miyai, Hirofumi Mizuno, Hironari Kato, Koichiro Tsutsumi, Daisuke Uchida, Akinobu Takaki, Hiroyuki Okada, Manabu Morita
    Oncology Reports.2016; 36(4): 2375.     CrossRef
  • Surgical Therapy of Cholangiocarcinoma
    Arnold Radtke, Alfred Königsrainer
    Visceral Medicine.2016; 32(6): 422.     CrossRef
  • 14,303 View
  • 182 Download
  • 40 Web of Science
  • 36 Crossref
Close layer
Role of Radiotherapy in the Multimodal Treatment of Ewing Sarcoma Family Tumors
Yunseon Choi, Do Hoon Lim, Soo Hyun Lee, Chuhl Joo Lyu, Jung Ho Im, Yun-Han Lee, Chang-Ok Suh
Cancer Res Treat. 2015;47(4):904-912.   Published online February 16, 2015
DOI: https://doi.org/10.4143/crt.2014.158
AbstractAbstract PDFPubReaderePub
Purpose
The aim of this study was to evaluate the role of radiotherapy (RT) in the management of Ewing sarcoma family tumors (ESFT). Materials and Methods Retrospective analysiswas performed on 91 patientswith localized ESFT treated from 1988 to 2012. Primary tumor size was ≥ 8 cm in 33 patients. Surgery, RT, and combined surgery with RT were applied in 37, 15, and 33 patients, respectively.
Results
Median follow-up was 43.8 months. Forty-three patients (47.3%) showed recurrence or progressive disease. Twelve patients (13.2%) showed local failure after initial treatment. Thirty-nine patients (42.9%) experienced distant metastases. The 5-year overall survival (OS), progression-free survival, and local control (LC) were 60.5%, 58.2%, and 85.1%, respectively. According to treatment, 5-year LCwas 64.8% with RT and 90.2% with combined surgery and RT (p=0.052). Prognostic factors for OS were tumor size (≥ 8 cm, p < 0.001) and surgical resection (p < 0.001). In large tumors (≥ 8 cm), combined surgery and RT produced better LC compared to RT (p=0.033). However, in smaller tumors (< 8 cm), RT without surgery resulted in a similar LC rate as RT with surgery (p=0.374). Conclusion RT used for patients with unfavorable risk factors resulted in worse outcome than for patientswho received surgery. Smallertumors could be controlled locallywith chemotherapy and RT. For large tumors, combined surgery and RT is needed. Proper selection of local treatment modality, RT, surgery, or both is crucial in the management of ESFT.

Citations

Citations to this article as recorded by  
  • Renal Ewing sarcoma with extensive metastasis diagnosed via pulmonary thrombus
    Coplen D Johnson, Shivam S Shah, Eric Wallace, Chaitanya Ahuja
    BMJ Case Reports.2024; 17(11): e263370.     CrossRef
  • Primary Ewing’s Sarcoma of Body of Mandible, Multimodal Treatment with Excellent Spontaneous Bone Regeneration: a Case Report
    Rangila Ram, Priyanka Bhardwaj, Yogesh Bhardwaj, Narotam Ghezta, Ravi Bhatt, Pravesh Dhiman
    Journal of Maxillofacial and Oral Surgery.2023; 22(3): 554.     CrossRef
  • Ewing’s sarcoma masquerading as an odontogenic infection
    Rizwan Hamid, Ambika Gaur, Sunita Gupta, Ritu Garg
    Journal of Cancer Research and Therapeutics.2023; 19(Suppl 2): S950.     CrossRef
  • 18F‐FDG PET and PET/CT as a diagnostic method for Ewing sarcoma: A systematic review and meta‐analysis
    Nimish Seth, Ishith Seth, Gabriella Bulloch, Adrian Hang Yue Siu, Allen Guo, Rukmini Chatterjee, Michael MacManus, Leo Donnan
    Pediatric Blood & Cancer.2022;[Epub]     CrossRef
  • Management of Unresectable Localized Pelvic Bone Sarcomas: Current Practice and Future Perspectives
    Joaquim Soares do Brito, Miguel Esperança-Martins, André Abrunhosa-Branquinho, Cecilia Melo-Alvim, Raquel Lopes-Brás, João Janeiro, Dolores Lopez-Presa, Isabel Fernandes, José Portela, Luis Costa
    Cancers.2022; 14(10): 2546.     CrossRef
  • Radiation Therapy Dose Escalation in Unresectable Ewing Sarcoma: Final Results of a Phase 3 Randomized Controlled Trial
    Siddhartha Laskar, Shwetabh Sinha, Abhishek Chatterjee, Nehal Khanna, Jifmi Jose Manjali, Ajay Puri, Ashish Gulia, Prakash Nayak, Tushar Vora, Girish Chinnaswamy, Maya Prasad, Jyoti Bajpai, Shashikant Juvekar, Subhash Desai, Amit Janu, Venkatesh Rangaraja
    International Journal of Radiation Oncology*Biology*Physics.2022; 113(5): 996.     CrossRef
  • Adjuvant Radiotherapy for the Multimodal Treatment of Pediatric Ewing Sarcoma
    Gonca ALTINIŞIK İNAN, İpek Pınar ARAL, Tarık KARGIOĞLU, Arzu YAZAL ERDEM, Selma ÇAKMAKCI, Hüseyin Furkan ÖZTÜRK, Suheyla AYTAÇ ARSLAN, Yılmaz TEZCAN
    Medical Records.2022; 4(3): 304.     CrossRef
  • Sacral Ewing sarcoma with rib, lung, and multifocal skull metastases: A rare case report and review of treatments
    Chen Ye, Wei Wei, Xuebin Tang, Feng Li, Baoquan Xin, Qianqian Chen, Haifeng Wei, Shaohui He, Jianru Xiao
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Pelvic Ewing sarcoma: Should all patients receive pre-operative radiotherapy, or should it be delivered selectively?
    Johnathan R. Lex, Vineet Kurisunkal, Yoichi Kaneuchi, Tomohiro Fujiwara, Jenny Sherriff, Catrin Wigley, Jonathan D. Stevenson, Michael C. Parry, Lee M. Jeys
    European Journal of Surgical Oncology.2021; 47(10): 2618.     CrossRef
  • The patterns of distant metastasis and prognostic factors in patients with primary metastatic Ewing sarcoma of the bone
    Lei Zhang, Lu Xiong, Li-Mei Wu, Wen-Hui Shen, Ping Zhou, Chen-Lu Lian, Wen-Tong Zhang, San-Gang Wu
    Journal of Bone Oncology.2021; 30: 100385.     CrossRef
  • The Outcome of Children With Malignant Bone Tumors: A Single-Center Experience
    Mohammadreza Bordbar, Ali Sarfaraz, Sezaneh Haghpanah, Omidreza Zekavat, Soheila Zareifar, Tahereh Zarei
    Global Pediatric Health.2021;[Epub]     CrossRef
  • Ewing's sarcoma of the hip: A case report with no evidence of tumor recurrence and literature review
    Payam Mohammadhoseini, Samira Razzaghi, Mahdi Barazesh, Sajad Jalili
    Bone Reports.2021; 15: 101131.     CrossRef
  • Reconstruction after Subtotal Sacrectomy for Sacral Ewing’s Sarcoma Using Tibial Allograft Strut Grafting: A Case Report
    Ryosuke Hirota, Makoto Emori, Yoshinori Terashima, Kousuke Iba, Noriyuki Iesato, Ryunosuke Fukushi, Mitsunori Yoshimoto, Toshihiko Yamashita
    Case Reports in Oncology.2021; 14(1): 296.     CrossRef
  • Characteristics and prognosis of pelvic Ewing sarcoma: a SEER population-based study
    Li Chen, Cheng Long, Jiaxin Liu, Fei Xing, Xin Duan
    PeerJ.2019; 7: e7710.     CrossRef
  • Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect
    Sheng Wang, Dexi Zhou, Zhenyu Xu, Jing Song, Xueyi Qian, Xiongwen Lv, Jiajie Luan
    Current Drug Targets.2019; 20(11): 1180.     CrossRef
  • Risk analysis factors for local recurrence in Ewing’s sarcoma
    J. I. Albergo, C. L. L. Gaston, M. C. Parry, M. K. Laitinen, L. M. Jeys, R. M. Tillman, A. T. Abudu, R. J. Grimer
    The Bone & Joint Journal.2018; 100-B(2): 247.     CrossRef
  • In Vitro and In Vivo Characterization of a Preclinical Irradiation-Adapted Model for Ewing Sarcoma
    Mary Carroll Shapiro, Tien Tang, Atreyi Dasgupta, Lyazat Kurenbekova, Ryan Shuck, M. Waleed Gaber, Jason T. Yustein
    International Journal of Radiation Oncology*Biology*Physics.2018; 101(1): 118.     CrossRef
  • Comparison of the effects of local treatment strategies in non-metastatic Ewing sarcoma of bone
    Wen-Tong Zhang, Wen-Wen Zhang, Zhen-Yu He, Jia-Yuan Sun, Lei Zhang, Qing Xia, San-Gang Wu
    Expert Review of Anticancer Therapy.2018; 18(5): 501.     CrossRef
  • Ewing sarcoma of the head and neck: The Mayo Clinic experience
    Michael D. Olson, Kathryn M. Van Abel, Rebecca N. Wehrs, Joaquin J. Garcia, Eric J. Moore
    Head & Neck.2018; 40(9): 1999.     CrossRef
  • Hemipelvectomías tras sarcomas de localización pélvica de alto grado: pronóstico en condrosarcomas frente a otros tipos histológicos
    J. Arnal-Burró, J.A. Calvo-Haro, C. Igualada-Blazquez, P. Gil-Martínez, M. Cuervo-Dehesa, J. Vaquero-Martín
    Revista Española de Cirugía Ortopédica y Traumatología.2016; 60(1): 67.     CrossRef
  • Hemipelvectomy for the treatment of high-grade sarcomas: Pronostic of chondrosarcomas compared to other histological types
    J. Arnal-Burró, J.A. Calvo-Haro, C. Igualada-Blazquez, P. Gil-Martínez, M. Cuervo-Dehesa, J. Vaquero-Martín
    Revista Española de Cirugía Ortopédica y Traumatología (English Edition).2016; 60(1): 67.     CrossRef
  • Local therapy in non-metastatic primary Ewing sarcoma of the mandible and maxilla in children
    S.S. Qureshi, M. Bhagat, S. Laskar, S. Kembhavi, T. Vora, M. Ramadwar, G. Chinnaswamy, M. Prasad, N. Khanna, S. Shah, S. Talole
    International Journal of Oral and Maxillofacial Surgery.2016; 45(8): 938.     CrossRef
  • The Role of Radiotherapy in Local Control of Nonextremity Ewing Sarcomas
    Ozlem O. Akagunduz, Serra A. Kamer, Burcin Kececi, Bengu Demirag, Haldun Oniz, Mehmet Kantar, Nazan Cetingul, Dundar Sabah, Yavuz Anacak
    Tumori Journal.2016; 102(2): 162.     CrossRef
  • Ewing's sarcoma of bone tumor cells produces MCSF that stimulates monocyte proliferation in a novel mouse model of Ewing's sarcoma of bone
    B.S. Margulies, S.D. DeBoyace, T.A. Damron, M.J. Allen
    Bone.2015; 79: 121.     CrossRef
  • 14,589 View
  • 201 Download
  • 22 Web of Science
  • 24 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP